A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis

What Was Tested

This randomized controlled trial paper looks at Therapeutic nicotine (patch, non-peptide).

The Ohio State University Wexner Medical Center and Cleveland Clinic enrolled 50 consecutive subjects aged ≥ 18 years with active pulmonary sarcoidosis, based on symptoms (ie, dyspnea, cough) and objective radiographic evidence of infiltrates consistent with nonfibrotic lung disease.

Why It Was Studied

The effects of nicotine on the progression of pulmonary sarcoidosis are unknown.

ClinicalTrials.gov; No.: NCT02265874; URL: www.clinicaltrials.gov.

Who Took Part

According to the abstract, 50 subjects were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Each study group was compared at 26 weeks based on repeated measures of FVC, FEV1, quantitative lung texture score based on CT texture analysis, Fatigue Assessment Score (FAS), St.

George's Respiratory Questionnaire (SGRQ), and the Sarcoidosis Assessment Tool.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Blinding on both sides kept the subjects and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

What Was Measured

PubMed files the paper under topics including Administration, Cutaneous, Disease Progression, Forced Expiratory Volume, Lung, Nicotine, Nicotinic Agonists and Pilot Projects.

The authors tagged it with the keywords FVC, fatigue, granuloma, human, interstitial lung disease and nicotinic receptor.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 50 subjects.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Chest), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.